Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Biotech Showcase 2018
15 slides from Kazia Therapeutics's conference presentation, Jan 10, 2018
Slide 1: An emerging oncology developer with two clinical-stage programs
An emerging oncology developer with two clinical-stage programs Presentation to Biotech Showcase #BTS18 San Francisco, CA 9 January 2018
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 3: Investment Highlights
Investment Highlights 1 Oncology-focused biotech with two cancer therapies in clinical trials - GDC-0084 entering phase II in glioblastoma multiforme - Cantrixil in phase I in ovarian cancer 2 Well-differentiated assets, with lead program licensed from Genentech - GDC-0084: brain-penetrant dual PI3K
Slide 4: Kazia is focused on development of high-potential novel therapies for poorly-served cancers
Kazia is focused on development of high-potential novel therapies for poorly-served cancers Partner with big pharma for late-stage development to bring to market Bring in under-valued assets from other pharmaceutical companies Conduct focused clinical trials Identify optimal patient groups Understan
Slide 5: A strong team brings international experience in big pharma and early-stage biotech
A strong team brings international experience in big pharma and early-stage biotech Board Scientific Advisory Board Iain Ross Chairman Executive and Board roles in pharma and small biotech Bryce Carmine Deputy Chairman 36 years executive experience in Eli Lilly Steven Coffey Non-Executive Director C
Slide 6: Two clinical programs, with value-driving inflection points providing newsflow during 2018
Two clinical programs, with value-driving inflection points providing impactful newsflow during 2018 *MTD = Maximum Tolerated Dose GDC-0084 Glioblastoma Multiforme (GBM) Cantrixil Ovarian Cancer Brain-penetrant PI3K inhibitor, developed to completion of phase I by Genentech Third-generation benzopyr
Slide 7: Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung 14 million cancer cases per annum Breast Colon Prostate Stomach No clear cause or strong risk factors 3-4 months untreated survival 12-15 months average survival with treatment Any age, but most common in 60s
Slide 8: Current standard of care is essentially ineffective in up to 65% of GBM cases
Current standard of care is essentially ineffective in up to 65% of GBM cases Source: ME Hegi, A-C Diserens, T Gorlia, et al. (2005). N Engl J Med 352:997-1003 Standard of Care (‘Stupp Regimen’) Debulking surgery where possible Radiotherapy + temozolomide Temozolomide maintenance therapy 6 weeks 4w
Slide 9: The PI3K pathway is highly relevant to GBM, and GDC-0084 is well-differentiated within the class
The PI3K pathway is highly relevant to GBM, and GDC-0084 is well-differentiated within the class 1CW Brennan et al, Cell (2013), 155(2):462-477; 2Y Suzuki, et al. J Radiat Res (2010), 51(3):343 PI3K Activation in GBM PI3K Inhibitor Class is Diverse PI3K dysregulation is associated with a worse progn
Slide 10: The PI3K class has been further validated by approval of a second NCE in September 2017
The PI3K class has been further validated by approval of a second NCE in September 2017 Two PI3K inhibitors now successfully brought to market Zydelig (idelalisib) [Gilead] Aliqopa (copanlisib) [Bayer] Neither drug is brain-penetrant, so are unlikely to rival GDC-0084 Demonstrates that PI3K is a val
Slide 11: Previous GBM failures are well understood, and can inform development of new therapies
Previous GBM failures are well understood, and can inform development of new therapies Pharmacokinetic Failure Many small-molecule kinase inhibitors are not well brain-penetrant, and so reach insufficient concentration at the tumour Tumour Genetics & Heterogeneity Many driver mutations for GBM, but
Slide 12: Genentech's phase I of GDC-0084 established dosing and showed favourable safety
Genentech’s phase I of GDC-0084 established dosing and showed favourable safety Efficacy Signals Safety Phase I safety trial conducted by Genentech 47 patients enrolled with advanced glioma (grade 3/4); average of three prior lines of therapy Most common adverse events were oral mucositis and hyperg
Slide 13: GDC-0084 phase II study design in first-line setting is supported by clinician and regulatory feedback
GDC-0084 phase II study design in first-line setting is supported by clinician and regulatory feedback Debulking surgery prior to study entry Radiotherapy + temozolomide Maintenance temozolomide Maintenance GDC-0084 R Approximately 60 sites in 5-6 countries Will target patients who are resistant to
Slide 14: Brain metastases from non-CNS tumors represent long-term market expansion potential
Brain metastases from non-CNS tumors represent long-term market expansion potential Source: E Lim & N Lim (2012). Oncology. 26(7):652-9; PK Brastianos, SL Carter, S Santagata, et al. (2015). Discovery 5:1164 Overview Example: Breast Mets Estimated 100,000 - 200,000 cases/year in US ~10-25% adult can
Slide 15: www.kaziatherapeutics.com
www.kaziatherapeutics.com